Book by 30 June 2026 and get a 10% early-bird discount on all events starting on or after 25 August 2026. To the promotion
GMP search engine – look up GMP compliance regulations and news
In-use Storage Time of Reconstituted Medicines
Recommendation
16-18 June 2026
Management, Supply and Quality Assurance of Clinical Trials
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Council of Europe’s CD-P-PH/PC Committee (co-ordinated by the EDQM) has published a position paper on in-use storage times for reconstituted parenteral medicines. The new paper highlights a gap between the stability data submitted for marketing authorisations and clinical use, calling for regulatory requirements that better reflect hospital practices.
Background
Based on a 2024 survey of hospital pharmacists in Council of Europe member states, it notes that hospital pharmacies sometimes set longer in-use times than those stated in the SmPC (Summary of Product Characteristics) due to practical constraints. The paper cautions that extending storage beyond SmPC limits
- May compromise safety and efficacy,
- Occurs outside authorised conditions,
- Places responsibility on the healthcare professional performing the reconstitution.
It also identifies a mismatch between stability data used for marketing authorisation and real clinical use, calling for regulatory requirements that better reflect hospital practice and urging industry to generate additional in-use stability data and seek SmPC/package leaflet updates where justified.
For more information please see the Council of Europe position paper published in the EDQM Newsroom.
